DaRT Source Beta-Alpha Radiation Balance

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing diffusing alpha-emitter radiation therapy (DaRT) methods face challenges in ensuring effective tumor cell destruction near the tumor perimeter due to reduced alpha radiation efficacy caused by dense membrane structures and high blood supply, leading to incomplete treatment and potential healthy tissue damage from radon daughters.

Innovation Solution

Incorporating a low desorption probability and high activity alpha-emitting radionuclides, such as radium-224, with a coating to control radon release, combined with beta radiation, to enhance tumor cell destruction by increasing beta radiation without increasing systemic alpha radiation exposure.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If high radon release rate is used to destroy tumor cells, then tumor destruction efficacy is improved, but damage to distant healthy tissue increases

Engineering Contradiction:

Improvetumor destruction efficacyVSAvoiddamage to healthy tissue

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the radiation type parameter from pure alpha to combined beta-alpha, exploiting the different tissue penetration and biological effectiveness characteristics of beta versus alpha radiation to achieve better therapeutic ratio

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent uses a composite radionuclide system (radium-224) that emits both alpha and beta radiation, combining the high cell-killing efficacy of alpha particles with the longer-range tissue penetration of beta particles to treat tumor periphery while limiting distant healthy tissue damage

Inventive Principle:

Principle #40Composite materials

2Reliability

If alpha radiation is used to treat tumor perimeter, then cell destruction is improved, but efficacy is reduced due to dense membrane structures and high blood supply

Engineering Contradiction:

Improvecell destruction efficacyVSAvoidreduced efficacy at tumor perimeter

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the radiation type from alpha to beta for treating tumor perimeter, exploiting beta particles' longer range and ability to penetrate dense membrane structures and overcome the washout effect of high blood supply

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent applies different radiation types to different tumor regions: alpha radiation for the tumor core and beta radiation for the tumor perimeter, matching each radiation type's characteristics to the specific treatment challenge of each region

Inventive Principle:

Principle #3Local quality

3Productivity

If radium activity is increased to enhance treatment, then tumor destruction is improved, but radon daughters cleared through blood may damage distant healthy tissue

Engineering Contradiction:

Improvetreatment efficacyVSAvoiddamage to distant healthy tissue

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the radiation type parameter to include beta radiation, which has different clearance and tissue interaction characteristics than alpha radiation, allowing higher overall activity while limiting distant healthy tissue damage from beta particles' shorter effective range in cleared radionuclides

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The approach ensures thorough tumor cell destruction by balancing alpha and beta radiation, minimizing healthy tissue damage and improving treatment efficacy at the tumor perimeter.

Implementation Method 1

radium-223 or radium-224 atoms, which generate chains of several radioactive decays with a governing half-life of 3.6 days for radium-224 and 11.4 days for radium-223

Methodology Applied

Scientific EffectRadioactive decay: Radioactive Decay

Implementation Method 2

These radionuclides, and their own radioactive daughter atoms, spread around the source by diffusion up to a radial distance of a few millimeters before they decay by alpha emission

Methodology Applied

Scientific EffectDiffusion: Diffusion

Implementation Method 3

Ionizing radiation destroys cells by creating damage to their DNA. Alpha particles are a powerful means for radiotherapy since they induce clustered double-strand breaks on the DNA

Methodology Applied

Scientific EffectIonizing radiation: Radiation

Implementation Method 4

In addition to releasing alpha radiation, some of the daughter atoms release beta radiation

Methodology Applied

Scientific EffectBeta radiation: Radiation

Data Source

PatentEP4262888B1Diffusing alpha-emitters radiation therapy with enhanced beta treatment

Publication Date: 2026.02.04 ALPHA TAU MEDICAL LTD

Figure 1~4

AI summary

An interstitial source (21) including a base (22) suitable for implanting in a tumor and alpha emitting atoms (26) attached to the base (22), with a concentration of at least 6 µCi per centimeter length. The alpha emitting atoms (26) are attached to the base, with a desorption probability upon radioactive decay of not more than 30%.